Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose-limiting. We evaluated the efficacy and safety of lenalidomide monotherapy in patients with relapsed and refractory MM. Patients (n = 222) received lenalidomide 30 mg/day once-daily (days 1-21 every 28 days) until disease progression or intolerance. Response, progression-free survival (PFS), overall survival (OS), time-to-progression (TTP), and safety were assessed. Overall, 67% of patients had received Lenalidomide monotherapy has acceptable toxicities and is active in relapsed and refractory MM patients. These data support treatment with single-agent lenalidomide, as well as its use in steroid-sparing combination approaches. The study is registered at www.clinicaltrials.gov as #NCT00065351.
every 28 days) until disease progression or intolerance. Response, progression-free survival (PFS), overall survival (OS), time-to-progression (TTP), and safety were assessed. Overall, 67% of patients had received ≥ 3 prior treatment regimens. Partial response or better was reported in 26% of patients and minimal response or better was reported in 44%. There was no difference between patients who had received Lenalidomide monotherapy has acceptable toxicities and is active in relapsed and refractory MM patients. These data support treatment with single-agent lenalidomide, as well as its use in steroid-sparing combination approaches. The study is registered at www.clinicaltrials.gov as #NCT00065351.
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INTRODUCTION
Multiple myeloma (MM) is an incurable plasma cell malignancy, previously associated with a median survival time of less than 3 years. 1 In the US, it is estimated that there are 19, 920 new cases of MM per year and 10,690 deaths annually. 2 Autologous stem cell transplantation (SCT) is a treatment of choice for younger patients with MM, but almost all patients relapse and become refractory to treatment. 1, 3, 4 In relapsed patients, responses to treatment are characteristically short, with a median survival of less than one year in patients who have received ≥ 2 prior treatment regimens. 5 The introduction of novel agents has transformed the management of MM, with the impact of thalidomide, bortezomib and, most recently, lenalidomide improving treatment outcomes for patients with MM. 
. [7] [8] [9] It has shown clinical benefit as monotherapy in patients with relapsed or refractory MM in both phase I
and phase II studies, with a large randomized phase II trial concluding that a 30 mg dose given once-daily for 3 weeks, with 1 week off therapy, was both well tolerated and active compared with 15 mg given twice-daily. [10] [11] [12] The addition of low-dose dexamethasone in this study was also shown to be feasible and effective in patients progressing on lenalidomide alone, with responses observed in 29% of patients.
11
After the publication of two important phase III trials, lenalidomide in combination with dexamethasone was confirmed to have important efficacy in the treatment of patients with relapsed or refractory MM who have received at least one prior treatment regimen. 13, 14 This led to its approval by the US Food and Drug Administration, European Medicines Agency, and other regulatory boards. However, the addition of dexamethasone to lenalidomide has been associated with significant adverse events, especially when given at high doses, including deep-vein thrombosis (DVT), infections, and hyperglycemia. [13] [14] [15] It is, therefore, important to investigate steroid-sparing approaches for lenalidomide as part of MM therapy, and in particular for steroid-intolerant patients.
In this phase II study, we evaluated the efficacy and safety of single-agent lenalidomide (30 mg once-daily) in the treatment of patients with relapsed and refractory MM. Helsinki, and all patients gave written informed consent prior to entering the study. 
MATERIALS AND METHODS

This
Patient eligibility criteria
Statistical analysis
The probability of a response in each category was estimated using the proportion of patients meeting the criteria of each response category (ie, the number of patients with response in each category divided by the number of patients evaluated). Exact two-sided 95% confidence intervals for the probability of a response of at least PR were calculated. For TTP, duration of response, and OS the Kaplan-Meier procedure was used to characterize the survival function. Median time to events and the respective two-sided 95% confidence intervals were calculated for each of these variables.
To evaluate the impact of prognostic factors on response to lenalidomide, univariate and multivariate analyses were conducted using age (≤ 65 years, > 65 years), gender, ECOG performance status (0, 1, data throughout the study. The study is registered at www.clinicaltrials.gov as #NCT00065351.
RESULTS
Baseline characteristics
All 222 patients enrolled received at least one dose of lenalidomide and were included in both the intent-to-treat (ITT) and safety populations. Baseline demographic and diseaserelated characteristics of patients are shown in Table 1 
Response evaluation
In the ITT population, the primary end point of CR + PR was achieved in 26% (95% confidence interval [CI] 25.7-26.5), including 5 patients with CR (2%) and 53 with PR (24%) ( Table 2) . Forty patients had a MR (18%) giving an ORR (CR + PR + MR) of 44% (95% CI 43.7-44.6). During treatment with lenalidomide 48% of patients achieved stable disease. Of the 222 patients enrolled, 183 patients had a post-baseline M-protein measurement at cycle 2 or beyond; the ORR in this population was 51% (CR 3%, PR 29%, and MR 20%), with 32% of patients achieving a PR or better. The reasons for treatment discontinuation in the 39 patients without a post-baseline M-protein measurement at cycle 2 or beyond were: adverse events (n = 16); death (n = 9); lack of therapeutic effect as determined by the investigator (n = 9); patient withdrew consent (n = 4); and major protocol violation (n = 1). Table 2 ). In those who had received prior treatment with bortezomib, the ORR was 46% (44 of 96 patients), with 3 patients (3%) achieving a CR, 27 (28%) a PR, and 14 (15%) a MR. Among patients who had undergone prior SCT, the ORR was 39% (39 of 99 patients), including 3 patients with a CR, 21 with a PR, and 15 with a MR. In patients who had received prior treatment with thalidomide, the ORR was 41% (72 of 177 patients), including 3 patients (2%) who achieved a CR, 38 (22%) who achieved a PR, and 31 (18%) who achieved a MR. The ORR was 35% in patients who were refractory to prior thalidomide therapy (n = 20; defined as progression while receiving any thalidomide-containing regimen with no initial response), 25% in patients who relapsed following prior response to any thalidomide-containing regimen, and 43% in patients who were sensitive to treatment with thalidomide (Table 3) . 18 It should be noted that some patients in the above analyses were counted separately for each of these categories as they received > 1 prior treatment including thalidomide, bortezomib, or SCT prior to receiving lenalidomide.
Several factors were evaluated to determine if patients were associated with response to lenalidomide ( Table 4) . In univariate and multivariate analyses, no independent prognostic factors were identified as predictors of an inferior response to lenalidomide, including prior SCT or the number of prior anti-MM treatment regimens.
For
Time-to-progression, progression-free survival, and overall survival
In the ITT population, the median TTP was 5.2 months and the median PFS was 4.9 months (Table 5 , Figures 3 and 4 ) . The median duration of OS was 23.2 months (Table 5, Figure 5) and the 1-year survival rate was 67%. In patients who achieved CR, PR, or MR, both median TTP and median PFS were 10.4 months each, with a median OS of 28.0 months ( Table 5 ).
The 1-year survival rate in patients who achieved at least a MR was 79% and in those who achieved at least a PR was 73%.
Safety and lenalidomide dose management
The median daily dose of lenalidomide in the study was 25 mg (range, 5-30 mg) and the median duration of treatment was 4.2 months (range, 0.06-38.0 months), with 29% of patients receiving lenalidomide for 9 months or longer. Median duration of treatment was longer for patients who responded to lenalidomide therapy (8.9 months for those who achieved at least a MR, and 13.4 months for patients who achieved at least a PR), but there was no significant difference in median daily dose (22.9 mg for those who achieved at least a MR, and 21.4 mg for patients who achieved at least a PR). Reasons for treatment discontinuation were: lack of therapeutic effect as determined by the investigator (51%, n = 113); adverse event (16%, n = 35); patient withdrew consent (5%, n = 12); death (5%, n = 10); major protocol violation (1%, n = 2); lost to follow-up (1%, n = 2); and other (2%, n = 5).
Of note for patients who withdrew consent, the median duration of treatment was 3.0 months (range, 0.2-21.3 months) and ORR was 38%, with 1% achieving at least a PR. This suggests that 6% of patients discontinued treatment early in the course of the study, before the best response could be achieved.
Safety evaluation in all patients who received at least one dose of lenalidomide revealed that the most frequently reported grade 3 or 4 adverse events were neutropenia (60%), thrombocytopenia (39%), and anemia (20%) ( Dose reduction or interruption of study treatment due to an adverse event was required in 176 (79%) patients, with a median time to the first dose reduction or interruption of 43 days (range, 2.0-385 days). The most common reasons for lenalidomide dose modification were neutropenia (43%) and thrombocytopenia (28%). Growth factor support was required prior to dose reduction in 59% of patients (21%, 23% and 23% during the first 3, 6 and 12 months, respectively). Adverse events led to discontinuation of lenalidomide therapy in 39 (18%) patients, most frequently because of neutropenia (5%), thrombocytopenia (4%), and renal failure (3%). Renal failure leading to discontinuation of therapy was considered to be related to lenalidomide in 4 (2%) patients.
By the end of the study, 132 deaths were reported among the 222 subjects who were treated with lenalidomide. Of 22 patients who died within 30 days after the last dose of lenalidomide, 5 cases were assessed as possibly related to lenalidomide therapy, including myopericarditis, syncope, septic shock, pneumonia, cardiorespiratory arrest, sudden death, pulmonary embolism, neutropenia, thrombocytopenia, and anemia.
Patients proceeding to transplantation
A total of 25 (11.3%) patients proceeded to high-dose therapy including bone marrow transplantation and/or SCT. Of the 23 patients who underwent SCT, transplantation was 
DISCUSSION
The results of this phase II study demonstrate that lenalidomide monotherapy at a dose of 30 mg given once-daily is an active therapy producing meaningful long-term benefit in patients with relapsed and refractory MM. Importantly, patients who had received prior thalidomide or prior bortezomib responded, and the tolerability profile of this steroid-sparing approach, in an otherwise relatively sick population, was noteworthy.
Overall response rates with lenalidomide monotherapy were similar for patients who had received ≤ 2 prior treatment regimens versus ≥ 3 prior treatment regimens (45% vs 44%, respectively). Specifically, patients responded after prior treatment with either thalidomide (ORR 41%) or bortezomib (ORR 46%), or after undergoing prior SCT (39%) suggesting that lenalidomide is effective regardless of the type of prior therapy. Responses were also similar in patients who were relapsed, refractory, or sensitive to prior thalidomide treatment (ORR 35%, 25%, and 43%, respectively).
Patients treated with lenalidomide monotherapy in this study achieved a response rate (PR or better) of 26%, with overall median TTP and OS values of 5.2 months and 23.2 months, respectively. These results are comparable to those seen in the SUMMIT trial where patients refractory to prior chemotherapy were treated with bortezomib monotherapy for 7 months (ORR 26%, median TTP 7 months, and median OS of 17 months) 19, 20 Although the response rate with bortezomib in the APEX trial was higher (43%), the median TTP (6.2 months) and OS (29.8 months) values were only marginally higher than those seen in this study. 21 This difference could be attributed to the selection criteria of the APEX study as it enrolled less heavily-pretreated patients (a median of 2 prior therapies) and excluded patients who were
For personal use only. on . by guest www.bloodjournal.org From refractory to dexamethasone. 22 Combination therapy with lenalidomide and dexamethasone produced response rates (PR or better) of 60-61%, median TTP of 11.1-11.3 months, and OS of 29.6 months. These results indicate that combination lenalidomide plus dexamethasone is more effective than lenalidomide alone in patients with relapsed or refractory MM. 13, 14 However, these studies also enrolled less heavily-pretreated patients (> 30% had only 1 prior therapy) and excluded patients who were resistant to dexamethasone.
The median OS in the present study is consistent with the OS reported in patients receiving single-agent lenalidomide at a dose of 30-mg once-daily and twice-daily (28 and 27 months, respectively) in the antecedent phase II randomized study, 11 and is among the highest reported in this heavily pretreated patient population. Also, in the current study the median PFS was 4.9 months compared with 7.7 months and 3.9 months seen in patients treated with lenalidomide once-daily and twice-daily, respectively. 11 Again, this likely reflects a more resistant population in the current study, as well as confirming that single daily-dosing is active.
11
Lenalidomide monotherapy had a remarkably manageable tolerability profile in this patient population. Neutropenia, thrombocytopenia, and anemia were the most frequently reported grade 3 or 4 adverse events, with the incidence of grade 4 adverse events relatively low.
Although the incidence of grade 3 or 4 neutropenia was reported in 60% of patients, febrile neutropenia was reported in only 4% of patients.
MM is associated with an increased incidence of venous thromboembolism, in the order of 5-10%, 23, 24 and treatment with lenalidomide in combination with high-dose dexamethasone has been shown to further increase the risk of venous thrombolic events in patients with relapsed or refractory MM. 13, 14 Therefore, the rate of grade 3 or 4 DVT observed during this study (4%) is at the lower end of what is expected in this patient population. Moreover, the 13 rate of DVT in the current study is consistent with that observed with lenalidomide monotherapy in MM.
11, 25 As well as the treatment being steroid-free, anticoagulant use in almost half of the patients enrolled may have contributed to the relatively low rate of confirmed DVT in this study.
Myelosuppression was managed by dose interruption or reduction, and growth factor support. Importantly, no grade 3 or 4 treatment-related peripheral neuropathy was observed and grade 2 events occurred in only 3% of treated patients. Overall, the safety data demonstrate that lenalidomide monotherapy, especially as a steroid-sparing approach, was generally well tolerated when administered to patients with relapsed and refractory MM.
The encouraging side-effect profile and promising activity shown by lenalidomide monotherapy provide a powerful platform for rationally informed combinations with other agents, and preliminary results are very favorable. [26] [27] [28] Ongoing studies are investigating various lenalidomide-based combination options including bortezomib with or without dexamethasone, bevacizumab plus dexamethasone, and CCI-779. 26, 28 In conclusion, the encouraging ORR, duration of response, TTP, and OS results of this study demonstrate that oral lenalidomide monotherapy at a dose of 30 mg once-daily is an effective and well tolerated therapy for patients with relapsed and refractory MM. These data provide a strong rationale for the use of lenalidomide as a single-agent in selected patients, in steroid-sparing combination approaches, an important consideration in this patient population, and as maintenance therapy. Further studies in these settings are currently ongoing. 112 (50) 26 (12) 13 ( 18 (8) 55 (25) 47 (21) 102 (46) Prior therapies, n (%) Partial response (PR) 53 (24) 18 (25) 35 (23) 38 (22) 27 (28) Minimal response (MR) 40 (18) 14 (19) 26 (17) 31 (18) 
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